| September 2010 | ||||||
|---|---|---|---|---|---|---|
| S | M | T | W | T | F | S |
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | ||
Monthly Archives
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
October 2008
September 2008
August 2008
July 2008
June 2008
April 2008
Complete Archives
Most recent entries
SpectraScience Provides Corporate Update and Outlook
SpectraScience appoints Sheldon L. Miller Esq. to its Board of Directors
SpectraScience Receives Notification of Pending Issuance of Two Patents
SpectraScience Retains Quorum Consulting
SpectraScience to Exhibit at Digestive Disease Week in New Orleans
SpectraScience Has Second Unannounced Inspection by FDA
SpectraScience’s Jim Hitchin Featured in MDDI Magazine Article
Health Radio - Interview with CEO, Jim Hichin
Professor Andreas Stallmach Chooses WavSTAT(R) Optical Biopsy System for Early Cancer Detection
SpectraScience CEO Jim Hitchin Speaks to Blogtalkradio About Better Cancer Screening Diagnostics
SpectraScience, Inc. Selects CWR & Partners as Its Public Relations Agency of Record
SpectraScience Forms Advisory Board - Governor Tommy Thompson to be Chairman
SpectraScience Releases Shareholder Newsletter
SpectraScience Engages European Contract Research Organization to Manage Clinical Trials
SpectraScience Awarded Japanese Patent 4361683 for Its Optical Biopsy Forceps System
News
SpectraScience to Exhibit at Digestive Disease Week in New Orleans
Apr 27, 2010
SAN DIEGO,April 27, 2010 (PR NEWSWIRE) - SpectraScience, Inc. (OTCBB:SCIE),a San Diego based medical device company, announced today that its senior management team will exhibit atDigestive Disease Week (DDW) in New Orleans, May 2-5.
DDW is the world's leadingconference for gastrointestinal clinicians and scientists. Approximately 16,000 GI professionalsattend each year. 270 leadingmanufacturers from around the world will display their products and/orservices. SpectraScience's teamwill be available at the Morial Conference center, Booth 223. To schedule ameeting with SpectraScience or for more information, call Jim Hitchin at (858)847-0200.
SpectraScience holds approximately 60 patents worldwide that have beenissued or are pending on its WavSTAT® Optical Biopsy System and LUMA®Cervical Imaging Systems. Thesedevices are used to assess tissue quickly to help determine if it is normal,pre-cancerous, or cancerous. The WavSTAT and LUMA Systems are approved by theFDA for detecting pre-cancerous and cancerous tissue in the colon and cervix,respectively. An evaluation of theWavSTAT for detection of pre-cancers in the throat ("Barrett's esophagus") isbeing tested.
Forward-LookingStatements
This news release contains forward-looking statements within the meaningof Section 27A of the Securities Act of 1933, as amended, and Section 21E ofthe Securities Exchange Act of 1934, as amended. These forward-looking statementsinvolve risks and uncertainties that may cause SpectraScience's actual resultsto differ materially from results discussed in forward-looking statements.Readers are urged to carefully review and consider the various disclosures madeby SpectraScience in this news release, its most recent Form 10-K and inSpectraScience's other reports filed with the Securities and ExchangeCommission ("SEC") that attempt to advise interested parties of the risks andfactors that may affect SpectraScience's business. These forward-lookingstatements are qualified in their entirety by the cautions and risk factorsfiled by SpectraScience in its annual report on Form 10-K and other documents.
AboutSpectraScience, Inc.
SpectraScience is a San Diego based medical device company that designs,develops, manufactures and markets spectrophotometry systems capable ofdetermining whether tissue is normal, pre-cancerous or cancerous withoutphysically removing tissue from the body. The WavSTAT Optical Biopsy Systemuses light to optically scan tissue and provide the physician with an immediateanalysis. With FDA approval for sale in the U.S. and the CE Mark for theEuropean Union, the WavSTAT System is the first commercially available productthat incorporates this innovative technology for clinical use. The Company'sLUMA imaging technology has received FDA approval for an optical non-invasivesystem that is proven to more effectively detect cervical cancer precursorsthan conventional methods available in the market today.
Contact:
SpectraScience, Inc.
Jim Hitchin, Chief Executive Officer
(858) 847-0200 x201
Hayden Communications
Investor Relations
Todd Pitcher
(858)-518-1387